Home / Healthcare/ FDA approves two new HIV drugs from Merck

FDA approves two new HIV drugs from Merck


Comments / {{hitsCtrl.values.hits}} Views / Monday, 3 September 2018 00:00


Reuters: Merck and Co Inc. said on Thursday the US Food and Drug Administration approved two of its HIV oral drugs, nearly two months ahead of schedule.

The drugs have been approved to treat adults with the most common strain of the virus, HIV-1, and target patients who have received no prior antiretroviral treatment, Merck said.

Delstrigo, a once-a-day combination tablet, has been approved with a boxed warning, the agency’s strictest, to flag risk of worsening hepatitis B infection.

Pifeltro, the second drug, is an oral medicine to be administered in combination with other antiretrovirals, Merck said.

Merck said it expects to stock both the treatments through wholesalers within a month.

More than 70 million people have been infected with the HIV virus and about 35 million have died since the beginning of the epidemic, according to the World Health Organization.

There is no vaccine to prevent HIV/AIDS with current treatments only helping patients to manage the disease. However, the fast-mutating virus has proved a challenge to the medical community as it often develops resistance to existing medicines.

Gilead Sciences and GlaxoSmithKline have dominated the market for HIV/AIDS treatments and sell therapies that generate billions of dollars.

 


Share This Article


DISCLAIMER:

1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.

COMMENTS

Today's Columnists

Laurels of ‘Living Together’: Refreshing reflections

Tuesday, 25 September 2018

It was a memorable evening with a mega gathering for a meaningfully different reason. It was not just another book launch with ego-boosting speeches about the author. It was also not an event where a popular politician coming late and preaching about


The fate of the rupee: Central Bank is caught with ‘Devil’s Alternative’

Tuesday, 25 September 2018

Not all are losing when the rupee depreciates The recent depreciation of the rupee against the US dollar in the market has apparently driven the entire nation to a panic mode. While it had been a field day for the media and opposition law makers, the


Southbound rupee and northbound CoL

Tuesday, 25 September 2018

The Sri Lankan Rupee hit a record low of 170 per $ last week, and the Minister of Finance warns of further depreciation. This is inevitable given the chaotic state of the nation’s economy. While the rupee turns south, CoL (cost of living) has no o


In the desert of Tamil films, actor Sivaji Ganesan was an oasis

Saturday, 22 September 2018

‘Indian Film,’ first published in 1963 and co-authored by former Columbia University Professor Erik Barnouw and his student Dr. Subrahmanyam Krishnaswamy, is considered a seminal study of the evolution and growth of Indian cinema. The book is cit


Columnists More